Indoximod

Indoximod (1-Methyl-D-tryptophan) is an orally active indoleamine 2,3-dioxygenase (IDO) pathway inhibitor. Indoximod acts as a Trp mimetic in regulating mTOR. Indoximod is an immunometabolic adjuvant used for the research of cancer[1][2].

Product Specifications

CAS Number

[110117-83-4]

Product Name Alternative

1-Methyl-D-tryptophan; NLG-8189

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Indoleamine 2,3-Dioxygenase (IDO)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Indoximod.html

Purity

99.85

Solubility

0.5 M NaOH : 66.67 mg/mL (ultrasonic) |DMSO : 0.55 mg/mL (ultrasonic; warming) |H2O : 5 mg/mL (ultrasonic; adjust pH to 2 with HCl)

Smiles

N[C@H](CC1=CN(C)C2=CC=CC=C12)C(O)=O

Molecular Formula

C12H14N2O2

Molecular Weight

218.26

Precautions

H302, H315, H319, H335

References & Citations

[1]Hou DY, et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophancorrelates with antitumor responses. Cancer Res. 2007 Jan 15;67 (2) :792-801.|[2]Metz R, et al. IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan. Oncoimmunology. 2012;1 (9) :1460-1468.